Cardiff R D
Department of Pathology and University of California-Davis Center for Comparative Medicine, County Road 98 and Hutchison Drive, UC-Davis, Davis, CA 95616, USA.
Microsc Res Tech. 2001 Jan 15;52(2):224-30. doi: 10.1002/1097-0029(20010115)52:2<224::AID-JEMT1007>3.0.CO;2-A.
In March 1999, a panel of distinguished pathologists was convened by the U.S. National Institutes of Health Breast Cancer Think Tank to develop a classification of breast lesions based on their examination of 39 models of Genetically Engineered Mice (GEM) associated mouse mammary cancer (Cardiff et al., 2000). The meeting, in Annapolis, Maryland, resulted in a published summary report from the Pathology Panel (Cardiff et al., 2000). The Annapolis consensus report, developed from the Panel's deliberations, pointed out that the mammary lesions of GEM were different from most (spontaneous) mouse mammary tumors and could be divided into three distinct categories: (1) lesions that resemble those found in spontaneous mouse mammary tumorigenesis, (2) lesions that have a unique "signature" tumor phenotype that was specific for the transgene, and (3) lesions that resemble those found in human breast diseases (Cardiff et al., 2000). This review emphasizes the proposed nomenclature and the differences between the models and human breast cancer with the intention of stimulating discussion and the development of new models.
1999年3月，美国国立卫生研究院乳腺癌智囊团召集了一个杰出病理学家小组，基于对39种基因工程小鼠（GEM）相关小鼠乳腺癌模型的研究，制定乳腺病变分类标准（卡迪夫等人，2000年）。在马里兰州安纳波利斯召开的会议形成了病理小组的一份已发表总结报告（卡迪夫等人，2000年）。根据小组的审议结果制定的安纳波利斯共识报告指出，基因工程小鼠的乳腺病变与大多数（自发）小鼠乳腺肿瘤不同，可分为三个不同类别：（1）类似于自发小鼠乳腺肿瘤发生中发现的病变；（2）具有特定于转基因的独特“标志性”肿瘤表型的病变；（3）类似于人类乳腺疾病中发现的病变（卡迪夫等人，2000年）。本综述强调了所提议的命名法以及模型与人类乳腺癌之间的差异，旨在激发讨论并推动新模型的开发。
